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Human immunodeficiency virus type 1 (HIV-1) typically uses CCR5 as a coreceptor and requires 
a high surface density of its CD4 receptor to target replication in CD4+ T cells. HIV-1 can evolve to enter 
cells with low surface density CD4. This phenotype is frequently observed in the central nervous system 
(CNS) of people with HIV-associated dementia (HAD). The putative CNS target cells are macrophage and 
microglia, both with low CD4. The liver also contains abundant macrophages. I hypothesized that 
macrophage-tropic variants can travel from the CNS and replicate in liver macrophage. To test this, I 
generated viral env genes from blood, cerebrospinal fluid (CSF), and liver from four people with HAD and 
assessed the entry phenotype to determine if any used low CD4. I found little evidence of macrophage-
tropic HIV-1 in the liver but the presence of viral recombinants suggests the virus can travel to the liver 
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CHAPTER 1: INTRODUCTION 
HIV-1 Pandemic 
Human immunodeficiency virus type 1 (HIV-1) is the cause of acquired immunodeficiency 
syndrome (AIDS) when untreated infection progresses by depleting CD4+ T cells in the peripheral blood 
and in tissues ultimately leading to impaired immune function. People living with HIV-1 (PLWH) with 
depleted CD4+ T cells are susceptible to opportunistic infections and other comorbidities. Without 
treatment, HIV-1 infection will progress to AIDS in an average of 8 years, and most people will die within 
a few years of an AIDS diagnosis. There are approximately 38 million people living with HIV-1 today [1].  
 The implementation of combination antiretroviral therapy (cART) in the mid-1990s drastically 
improved the prognosis of people living with HIV-1. HIV-1 has become a manageable chronic health 
condition, and cART enables PLWH people to live long, healthy lives. In 2019, 68% of adults and 53% of 
children living with HIV-1 globally were receiving lifelong cART [1]. However, with gaps in HIV-1 care, 
globally 690,000 people died from HIV-related causes and 1.7 million people were newly infected with 
HIV-1 in 2019. World-wide efforts are underway to increase the percentage of infected people who are 
diagnosed, treated, and virally suppressed though the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) Fast-Track strategy and the World Health Organization’s (WHO) “treat-all” approach where all 
infected persons are recommended to receive cART immediately after diagnosis [1] [2].  
 While cART effectively manages HIV-1 disease, there is currently no cure. cART can suppress 
viral loads to undetectable levels as long as the drugs are consistently taken. If cART is interrupted, the 
virus rebounds and resumes productive infection. This viral persistence in cellular and anatomical 
reservoirs is the main barrier to a cure. Identifying and characterizing these reservoirs is essential to 





HIV-1 genome organization and viral life cycle 
HIV-1 is an enveloped virus with a single-stranded RNA (ssRNA) genome in the Retroviridae 
family and lentivirus genus. The HIV-1 genome is ~9 kilobases in length with a 5’ cap and a 3’ poly A tail 
and encodes for 10 genes, gag, pro, pol, env, vif, vpr, tat, rev, vpu, and nef, and in the DNA form the viral 
genome is flanked by long terminal repeats (LTR). The gag gene and the env gene encode the structural 
proteins; the Gag polyprotein precursor (matrix, capsid, nucleocapsid) and the viral envelope Env protein, 
respectively. The viral enzymes, protease (PR), reverse transcriptase/RNase H (RT), and integrase (IN) 
are encoded by the pro and pol genes. The remaining genes encode regulatory proteins (Tat and Rev) or 
accessory proteins (Vif, Vpr, Vpu, Nef) [3].  
The first step of the HIV-1 replication cycle is attachment to a permissive cell via interactions 
between the HIV-1 Env protein and the cell-surface receptor CD4 and coreceptors CCR5 or CXCR4. HIV-
1 Env is a heavily glycosylated, hetero-trimeric protein composed of three copies of the gp120 surface 
glycoprotein and three copies of gp41, the transmembrane glycoprotein embedded in the viral membrane 
[4]. Viral attachment to the cell begins with gp120 binding to CD4 on the cell surface. This interaction 
induces conformational changes in gp120 that facilitate interaction between gp120 and the coreceptor 
CCR5 or CXCR4. Co-receptor binding leads to additional conformational changes in gp120 that expose 
the fusion peptide at the N terminus of gp41 which can then insert into the host cell membrane and tether 
the virion to the target cell [4]. Once tethered, the three gp41 monomers in the Env trimer interact through 
a helix near their N terminus which then interacts with a helix downstream to form a stable six-helix 
bundle. This six-helix bundle brings the host and viral membranes close together and drives creation of 
the fusion pore through which the contents of the viral particle are delivered to the host cell cytoplasm [4].  
Once the viral core is release into the cytoplasm, the viral  RNA is reverse transcribed into DNA 
by the viral DNA polymerase RT. The viral genomic DNA enters the nucleus with several viral proteins 
interacting with the nuclear pore. In the nucleus, the viral integrase enzyme mediates integration of the 
viral DNA genome into host DNA [5]. Integration can happen at any location in the host genome but it 
occurs more often in transcriptionally active genes due to the interaction of the integrase protein with 
cellular proteins targeting these regions [5]. This integration step is a crucial part of the viral life cycle and 
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is the mechanism by which HIV-1 can persist in a host even if cART effectively prevents new rounds of 
viral replication.  
The HIV-1 provirus can then be transcribed by host cell machinery (RNA Pol II) and viral 
transcripts, spliced or unspliced, are transported out of the nucleus with the help of the viral Rev protein 
[6]. In the cytoplasm, these transcripts are then translated into viral proteins or packaged into an 
assembling virion [7]. Viral assembly occurs at the surface of the cell where two copies of the unspliced 
viral RNA genome and viral proteins are packaged into an immature viral particle that buds from the cell 
membrane. The highly ordered process of the cleavage of the polyprotein precursors Gag and Gag-Pro-
Pol by the viral protease leads to the formation of a mature, infectious viral particle [8].  
 
HIV-1 Latency and viral reservoirs 
 HIV-1 persistence in cellular and anatomical reservoirs is the barrier to a cure. Combination 
antiretroviral therapy (cART) stops viral replication by preventing new cells from being infected and halts 
the progression of disease. However, upon discontinuation of cART, the virus rapidly rebounds. These 
cells that are able to harbor the HIV-1 genome and produce infectious virions after years of suppressive 
therapy comprise the latent reservoir. In people on cART, the overwhelming majority of proviral genomes 
are defective. While these defective genomes may contribute to ongoing immune activation, they are not 
able to re-establish a productive infection. The minority of proviral genomes that are intact comprise the 
replication competent reservoir which is responsible for viral rebound and disease progression upon 
cART discontinuation.  
 Activated CD4+ T cells are the most permissive cell type for HIV-1. Latently infected resting 
memory CD4+ T cells are the most studied and best characterized HIV-1 reservoir in people on cART [9-
11]. The quantitative viral outgrowth assay (QVOA), which measures the number of resting memory 
CD4+ T cells that can be induced to produce replication competent virus, is one quantitative measure of 
the reservoir. Studies using this assay have estimated that in PLWH on cART, approximately one in a 
million resting CD4+ T cells can be induced to produce replication competent virus and this reservoir has 
a half-life of 44 months [12, 13]. It is also possible for latently infected T cells to clonally expand adding 
another mechanism of persistence [14-17].  
 4 
 
 Resting memory T cells reside not only in the peripheral blood but also in various tissues. 
Lymphoid tissues as well as the gut and other mucosal sites are of particular interest given the high 
numbers of T cells in these tissues [18, 19]. Characterizing the HIV-1 proviruses in these tissues 
specifically is a current active area of research. It is important to know if the pathogenesis of the potential 
reservoir in tissues is similar to the well-studied reservoir in peripheral blood mononuclear cells (PBMCs) 
when assessing strategies for a cure. For example, are latency reversing agents (LRAs) as effective at 
stimulating tissue T cells in vivo as they are at stimulating resting T cells in the periphery? Additionally, 
are there other cell types in tissues that can support HIV-1 replication and therefore potentially contribute 
to the latent reservoir? 
 
HIV-1 central nervous system (CNS) disease  
 Soon after the discovery of HIV-1 as the causative agent of AIDS, the presence of HIV-1 in the 
brain was identified [20]. HIV-1 can be detected in the cerebrospinal fluid (CSF) of infected persons as 
early as 8 days post infection indicating the potential for HIV-1 to affect the CNS early as part of systemic 
disease [21]. The association between AIDS presentation and various neurological complications was 
also described soon after the identification of HIV-1 [22]. HIV-1 infection of the CNS can cause a wide 
range of neurocognitive dysfunction ranging from mild impairment to full-blown dementia (HIV-associated 
dementia, HAD), diseases with the umbrella designation HIV-associated neurocognitive disorders 
(HAND). With the advent of cART, the incidence of HAD has decreased dramatically but milder forms of 
HAND have increased resulting in a current level of PLWH presenting with some form of neurocognitive 
dysfunction at ~50% [23].  
 The CNS is an anatomical compartment isolated from the rest of the body by the blood brain 
barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) [24]. The BBB and BCSFB are 
semipermeable barriers that exist to limit the exchange of solutes between the peripheral blood and the 
CNS. The CSF is considered an immunologically active fluid as it contains T cells, B cells, and monocytes 
[24]. T cells are primarily restricted to the CSF but monocytes can enter the brain and differentiate into 
macrophages that tend to stay close to the CNS vasculature (perivascular macrophages) but can also be 
found in other parts of the brain (meninges and choroid plexus). CNS myeloid cells and microglia (brain 
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resident macrophages) have antigen-presenting capability and are considered important for CNS immune 
surveillance and interactions with circulating memory T cells.  
 HIV-1 is detected in the CSF of nearly all PLWH not on cART [25] but the mechanisms by which 
the virus enters the CSF/CNS are not well understood. One theory is that HIV-infected CD4+ T cells 
traffic into the CNS either as part of routine immune surveillance or as a consequence of 
neuroinflammation. The alternative theory is that individual HIV-1 particles cross the BBB/BCSFB, most 
likely in the setting of a high blood viral load. Neuroinflammation can be a protective immune response to 
tissue damage in the CNS but the inflammation and immune activation can also compromise the 
BBB/BCSFB altering the CNS homeostasis and potentially making the CNS more susceptible to HIV-1 
virions and HIV-infected cells. Neuroinflammation has been well documented in PLWH with the common 
occurrence of elevated CSF white blood cell (WBC) counts as well as elevated levels of inflammatory 
chemokines and cytokines [26, 27].  
 The detection of HIV-1 in the CNS does not indicate whether the virus is being trafficked into the 
CNS (by infected cells or as free virions) or if the virus is replicating locally. One way to clarify this is by 
sequencing the virus and comparing it genetically to virus in the peripheral blood. In these types of 
studies, the CSF is used as an accessible proxy for the CNS as a whole. If the viral populations in the 
CSF and the blood are equilibrated, that is the two populations are genetically similar, it is likely the virus 
detected in the CSF has been trafficked from the blood. Alternatively, if the viral population in the CSF is 
heterogenous and compartmentalized, or genetically distinct from virus in the periphery, this pattern 
would indicate the virus has been replicating independently over time within the CNS compartment. It is 
also possible that a viral population in the CSF could be homogenous and compartmentalized. In this 
instance, it is likely a transient phenomenon where HIV-infected cells have been clonally amplified and 
released virus in the CSF/CNS. This clonal amplification may or may not lead to an established local 
infection.  
 Locally replicating HIV-1 populations in the CSF/CNS have been identified within the first two 
years of infection [28] and there are high rates of locally replicating populations in the CSF/CNS of PLWH 
with severe neurological disease [29]. The ability of HIV-1 to replicate in the CSF/CNS suggests this 
compartment could be a potential viral reservoir site. Identifying and characterizing the cell type or types 
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in the CNS in which HIV-1 could sustain replication is an important part of characterizing the CNS as a 
potential reservoir. Elevated CSF WBC counts in the CNS is common among HIV-1 individuals [30], and 
moreover, the inflammation accompanying elevated CSF WBC levels can lead to BBB dysfunction. Both 
of these scenarios could result in increased numbers of CD4+ T cells in the CSF/CSN i.e., an increased 
number of target cells for HIV-1. However, all PLWH with evidence of CNS replication do not have 
elevated CSF WBC counts and there are additional permissive cell types in the CNS (macrophages, 
microglia) raising the possibility of CNS reservoirs in cell types other than CD4+ T cells. While it is clear 
HIV-1 can infect cells in the CNS, it remains unclear whether these cells can become a part of the latent 
reservoir by harboring proviral DNA during suppressive cART.  
 
HIV-1 target cells in the CNS 
 In healthy individuals, there are relatively few T cells in the CNS; less than 1% of T cells in the 
blood are present in the CSF and even less still in the brain parenchyma [24]. Though the proportion of T 
cells is low in the CNS, most of the CD4+ T cells in the CNS are permissive to HIV-1 infection (activated 
memory T cells) [24]. Additionally, proinflammatory conditions promote an influx of immune cells into the 
CSF/CNS thus increasing the number of potential target cells. Evidence of HIV-1 replication in the CNS in 
CD4+ T cells has been observed in untreated people as well as people with neurosymptomatic CSF 
escape ( [31], Joseph and Kincer, unpublished).  
 In addition to CD4+ T cells, perivascular macrophages are resident CNS cells that express the 
necessary cellular receptors for HIV-1 infection. In contrast to CD4+ T cells, which have a high density of 
CD4 on the cell surface, macrophages have a low surface density of CD4 [32]. Most HIV-1 is R5 T cell-
tropic, meaning it requires a high density of CD4 to enter a cell and it uses the coreceptor CCR5 (rather 
than CXCR4) [33]. R5 T cell-tropic viruses are unable to efficiently infect cells with low surface densities 
of CD4 and therefore these viruses would be unable to sustain replication in a cell like a macrophage 
[32]. Macrophage-tropic viruses are almost never observed in the blood and have primarily been found in 
the CNS [28, 29, 31, 34, 35]. This ability to use low levels of CD4 for cell entry is an evolved feature of the 
viral Env protein. This transition in phenotype cannot be attributed to a single genetic mutation but rather 
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involves multiple genetic changes that may differ between people as the virus adapts to the lack of CD4-
rich target cells in the CNS [36].  
 Microglia and astrocytes are two additional CNS cell types that have been suggested to be 
involved in HIV-1 infection. Microglia are CNS tissue-resident macrophages-like cells and are the 
predominant immune cell in the brain parenchyma. Like macrophages, microglia have a low surface 
density of CD4 suggesting they are permissible to HIV-1 infection [37]. Further, studies of autopsy tissue 
have shown microglia can contain HIV-1 protein and nucleic acid, and microglia can be infected with HIV-
1 in vitro [37]. Conversely, astrocytes do not express CD4 [38]. Therefore, even though HIV-1 DNA has 
been reported to be present in astrocytes of PLWH [39], it seems unlikely astrocytes can be infected in 
vivo.   
 
Macrophages and HIV-1 target cells in the liver 
 When evaluating the CNS as a potential anatomical reservoir for HIV-1 infection, it is necessary 
to consider both T cells and macrophages as potential cellular reservoirs. HIV-1 infection in T cells has 
been well characterized in lymphoid tissues and in the peripheral blood, and it is known that CD4+ T cells 
infected with HIV-1 can become latent and maintain the ability to produce infectious virus (as 
unexpressed viral DNA) in a reservoir throughout treatment with cART. In contrast, HIV-1 infection in 
macrophages has primarily been identified in the CNS [28, 31, 34, 40] and on one occasion in the male 
genital tract [41]. Little is known about the extent to which macrophage infection may contribute to the 
latent reservoir. As mentioned previously, macrophage tropism is thought to evolve as a necessity when 
the virus is in an environment with relatively low numbers of preferred high CD4 density T cells and 
relatively high numbers of low CD4 density macrophages. The CNS is an anatomical site with this type of 
target cell ratio. An additional anatomical site with high levels of macrophages is the liver.  
 Kupffer cells are the resident tissue macrophage in the liver. These cells account for ~10% of the 
cells in the liver making it the highest concentration of tissue macrophage in the body [42]. Unlike the 
CNS and the genital tract, blood flows freely through the liver suggesting this is not a site where 
macrophage tropism might evolve out of necessity but it may be possible that viruses that evolve the 
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macrophage-tropic phenotype in the CNS could travel outside the CNS and into the liver where they 
might continue to replicate in macrophage. 
 
HIV-1 and HCV 
 Liver-related disease is one of the leading causes of non-AIDS-related death in PLWH [43]. 
Untreated or poorly controlled HIV infection is an independent risk factor for liver fibrosis, and liver fibrosis 
is the most common pathway to hepatic injury. People living with HIV (PLWH) with treated and controlled 
disease are prone to developing common liver diseases such as alcoholic liver disease (ALD) and 
nonalcoholic fatty liver disease (NAFLD, occurs in 30-60% of HIV-infected people) [43]. Alcohol use is 
prevalent among PLWH and it has been reported that frequent alcohol use resulted in a decline in CD4+ 
T cell count below 200 cells/ul and higher viral loads [44, 45]. Additionally, alcohol use can suppress the 
innate and adaptive immune systems which can accelerate disease progression [46]. HIV-infection, or 
just presence of the gp120 Env protein, can promote direct profibrogenic effects on hepatic stellate cells 
(HSCs, the primary source of collagen in an injured liver), secretion of proinflammatory cytokines, and 
direct hepatocyte apoptosis [43]. 
 PLWH also have a high incidence of viral hepatitis. Between 5% - 25% of PLWH globally are 
estimated also to be infected with Hepatitis B virus (HBV) and 30% with Hepatitis C virus (HCV) [43]. 
Consequently, much of the research done on HIV-1 infection of the liver has been done on people who 
are coinfected with HIV-1 and HCV or HBV. As HCV and HBV are routinely screened for, and as viral 
hepatitis becomes easier to treat, the HIV-1 mono-infection and liver pathogenesis in HIV-1 disease are 
becoming more active areas of research [47].  
Multiple types of cells in the liver have been reported to be successfully infected with HIV-1 in 
vitro: HSCs, sinusoidal endothelial cells, and Kupffer cells, the resident macrophages of the liver [48]. In 
vivo, infection by HIV-1 has been most consistently demonstrated in Kupffer cells. CD4, CCR5 and 
CXCR4 have been detected on Kupffer cells in HIV-negative individuals suggesting that these cells are 
permissive to HIV-1 infection [49]. HIV-1 infection of Kupffer cells in untreated people has been shown by 
in situ hybridization for HIV-1 RNA and by PCR for proviral DNA in FACS-purified Kupffer cells from livers 
of people diagnosed with AIDS [50]. Additionally, simian immunodeficiency virus (SIV) studies in 
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nonhuman primates have led to interesting findings with regards to SIV pathogenesis in the liver. Namely, 
macaques infected with SIV see an increase in immune cell trafficking to the liver that resolves with 
cART, and during untreated infection there is a correlation between SIV burden and numbers of T cells 
and macrophages found in the liver of infected animals [51]. RNAscope/in situ hybridization has shown 




 Despite the availability of cART which can manage HIV-1 disease long term, more than half a 
million people died of HIV-1 in 2019 and over one and half million people were newly infected. HIV-1 uses 
the cellular receptor CD4 to facilitate entry into host cells and consequently preferentially infects CD4+ T 
cells. Most HIV-1 isolated from PLWH regardless of the tissue source or disease stage not only requires 
CD4 for entry but a high density of CD4 on the cell surface. In rare instances, HIV-1 can evolve the ability 
to infect CD4+ cells with a low surface density of CD4. This phenomenon has been shown most 
consistently in the CNS compartment where the relative lack of CD4+ T cells and availability of cell types 
expressing a low density of CD4 (macrophage and microglia) is thought to drive evolution. The highest 
concentration of tissue macrophage in the human body is in the liver. If it were possible for macrophage-
tropic virus to maintain their phenotype outside of the CNS, a macrophage-rich tissue such as the liver 
















CHAPTER 2: ASSESSMENT OF HIV-1 IN THE LIVER 
Introduction 
Human Immunodeficiency Virus Type 1 (HIV-1) replicates primarily in CD4+ T cells and most 
HIV-1 isolated from acutely or chronically infected PLWH requires a high density of CD4 on the surface of 
the target cell [33] [52] for entry. The expression of CD4 alone is not sufficient to make a cell permissive 
to HIV-1 infection as cells must also express a coreceptor, most often CCR5 [53]. HIV-1 variants with the 
ability to enter cells expressing low densities of CD4 have been isolated from the cerebrospinal 
fluid/central nervous system (CSF/CNS) of some PLWH, most often in people with an untreated infection 
and diagnosed with HIV-associated neurocognitive disorders (HAND) [29, 31]. Low CD4-using, or 
macrophage-tropic, HIV-1 is observed when CSF/CNS virus is genetically compartmentalized, that is the 
virus has been replicating and evolving in the CSF/CNS independently of the viral population in the blood. 
The hypothesis is that the virus adapts to an environment with relatively few high CD4-expressing cells by 
evolving the ability to infect cells with low levels of CD4, such as perivascular macrophages and microglia 
which are resident to the CNS. These macrophage-tropic variants are rarely observed in the blood [33] 
[54]. The clinical manifestations of HIV-1 CNS disease [55] make it an important anatomical compartment 
for understanding HIV-1 pathogenesis. However, there are additional macrophage-rich tissues in the 
body where macrophage-tropic HIV-1 could evolve or reside and these have received little attention in 
terms of factors driving the evolution of viral entry phenotype.  
 The genital tract is one such compartment of interest where urethral macrophages isolated from 
penile tissue of PLWH on suppressive cART have been reported to harbor replication competent 
proviruses [56] and where in one instance macrophage-tropic HIV-1 has been identified [41] . The largest 
concentration of tissue macrophage in the body, however, is in the liver [42], a tissue where HIV-1 viral 
populations have been largely unexplored. The tissue resident macrophages in the liver, Kupffer cells, 
account for ~10% of the cells in the liver [42]. Kupffer cells have been reported to express CD4, CCR5, 
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and CXCR4 [49] and there is evidence they can be infected with HIV-1 both in vitro and in vivo [48]. 
Taken together, these reports suggest Kupffer cells are permissive to HIV-1 infection. T cells are also 
abundant in the liver, passing through the tissue from the blood or the gut, and it has been proposed that 
resident memory T cells can stay in the liver tissue for years [57]. Uncontrolled HIV-1 infection is a risk 
factor for liver fibrosis and consequently hepatic injury in PLWH is associated with the development of 
common liver diseases [43]. Additionally, PLWH are commonly coinfected with a virus associated with 
hepatitis [43]. Due to the high incidence of liver disease, many PLWH have an inflammatory, fibrotic liver 
environment that may be conducive to viral replication in T cells and/or in macrophages/Kupffer cells.  
I hypothesized that the liver is an anatomical site where macrophage-tropic HIV-1 can replicate. 
The abundance of high CD4 target cells in the liver would suggest HIV-1 in the liver would not be subject 
to selective pressure that could drive the evolution of macrophage tropism; however, it may be possible 
that macrophage-tropic HIV-1 that evolved in the CNS may travel to the liver and replicate there. In this 
study, I examine a small cohort of people to look for such a pattern. Because macrophage-tropic HIV-1 
has most commonly been found in people with compartmentalized CSF virus [29, 31, 35] and in people 
with end-stage disease and HAND [29], I first identified participants that met these criteria by sequencing 
viral env genes from the blood plasma and CSF of participants diagnosed with HIV-associated dementia 
(HAD). Construction of phylogenetic trees allowed us to identify compartmentalized CSF lineages, and 
the entry phenotype was assessed for representative HIV-1 Env proteins from virus in the plasma and 
CSF of each participant to identify macrophage-tropic viruses. Once I characterized participants with 
compartmentalized, macrophage-tropic virus, I examined proviral DNA sequences from the liver and a 
representative lymphoid tissue taken at autopsy from these same participants. I compared the env gene 
sequences from all compartments for each participant in a phylogenetic tree to look for heterogenous 
compartmentalized populations within the tissue virus that would indicate local replication within a 
compartment and then assessed the entry phenotype of these viruses. Since this analysis is focused on 
ART-naïve participants, the provirus measured in cells represents active infectious events and not 
exclusively a latent reservoir though it is possible that some proviruses in latent cells were included in this 
analysis. The results indicated macrophage-tropic HIV-1 is not commonly found in the liver though the 
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observation of recombinant (between the macrophage-tropic CSF lineage and the T cell-tropic lineage) 
envs  in the liver suggest macrophage-tropic virus can indeed travel to the liver. 
 
Materials and Methods 
 Ethics statement: This study was approved by the Institutional Review Boards (IRB) at Mt Sinai 
University, the University of Texas at Galveston, and the University of North Carolina at Chapel Hill. All 
study participants were adults (≥ 18 years of age) and written informed consent was obtained.  
Study design: Participants were chosen from the National NeuroAIDS Tissue Consortium (NNTC) 
sample repository who met all of the following criteria: HIV+, HIV-associated dementia (HAD) diagnosis, 
CD4+ T cell count <250 cell/ul, and the availability of paired blood plasma and cerebrospinal fluid (CSF), 
as well as post mortem liver and lymphatic tissue. Participants were not excluded based on any other 
diagnosis or characteristic.  
Sample collection: The samples used in this study were collected at the University of Texas at 
Galveston in Galveston, Texas or Mt Sinai Medical Center in New York City, New York. All samples were 
distributed by the National NeuroAIDS Tissue Consortium (NNTC, funded by NIMH). Blood was collected 
in EDTA tubes, the plasma was separated from the whole blood by centrifugation and stored in aliquots at 
-80o C. CSF was collected and stored in aliquots at -80o C. Tissue samples were taken at autopsy and 
frozen.  
Single genome amplification: For the plasma and CSF samples, single genome amplification 
(SGA) was performed as previously described [33]. Briefly, 500 µl – 1 mL of blood plasma or CSF fluid 
was ultracentrifuged at 200,000 rpm to pellet virus, the supernatant was then removed and 140 µl was left 
behind to resuspend the viral pellet and extract the viral RNA (vRNA) using the QIAamp Viral RNA 
Extraction Kit (Qiagen). The vRNA was reverse transcribed using Superscript III Reverse Transcriptase 
(Invitrogen) and an Oligo dT20 primer to prime from the 3' poly A tail per the manufacturer’s instructions to 
generate cDNA. The cDNA was then diluted to end-point, in order to minimize the possibility of 
recombination between multiple viral variants during PCR, and semi-nested PCR was performed using 
Platinum Taq High Fidelity polymerase (Invitrogen). The first round PCR primers, F5010 (5′- 
TGCCAAGAAAAGCAAAGATCATTAG -3′) and LTRDN1 (5′-
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GACTCTCGAGAAGCACTCAAGGCAAGCTTTATTGAG-3′), were used to generate a half genome 
fragment starting in int, including full-length accessory genes, env gene, and nef gene, and ending in the 
3’ LTR and then the second-round primers, B5957 UP1 (5′-
GATCAAGCTTTAGGCATCTCCTATGGCAGGAAGAAG-3′) and LTRDN1 (5′-
GACTCTCGAGAAGCACTCAAGGCAAGCTTTATTGAG-3′) were used to generate an amplicon spanning 
from vpu through the 3’ LTR. Sanger sequencing was used to bidirectionally sequence full length env 
genes. Highlighter plots showing single nucleotide polymorphisms (SNPs) were generated using the 
highlighter tool on the Los Alamos National Laboratory HIV Sequence Database 
(https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html).  
Droplet digital PCR: For the tissue samples, a small piece of tissue (~0.01 gm) was excised from 
the total frozen tissue piece and total DNA was extracted using the Monarch Genomic DNA Purification 
Kit (New England Biolabs). The HIV-1 DNA in each sample was quantified using the droplet digital PCR 
(ddPCR) protocol described in Malnati et al. [58]. Briefly, a 96-well plate was prepared with duplicate 
LTRgag and RPP30 wells for each tissue sample as well as duplicate LTRgag and RPP30 negative 
controls, as well as duplicate positive control wells for each probe using DNA extracted from the 8E5 cell 
line (a CEM derivative cell line that contains integrated HIV-1 DNA, American Type Culture Collection, 
ATCC). LTRgag reactions were prepared with 3 µl of undiluted DNA and RPP30 reactions were prepared 
using 1 µl of DNA diluted 1:100. PCR master mixes were prepared using ddPCR Supermix for Probes (no 
dUPT) (Bio-Rad), primers (LTRgagF (5’-TCTCGACGCAGGACTCG-3’) and LTRgagR (5’-
TACTGACGCTCTCGCACC-3’) for LTRgag reactions, RPP30F (5’-GATTTGGACCTGCGAGCG-3’) and 
RPP30R (5’-GCGGCTGTCTCCACAAGT-3’) for RPP30 reactions), and probes (LTRgagP (5’-/56-
FAM/CTCTCTCCT/ZEN/TCTAGCCTC/31ABkFQ/-3’) for LTRgag reactions and RPP30P(5’- /56-
FAM/CTGACCTGA/ZEN/AGGCTCT/31ABkFQ/-3’) for RPP30 reactions). Once master mixes were 
prepared, droplets were generated using the Bio-Rad Automated Droplet Generator and then the plate 
was sealed PCR was conducted. Upon completion of the PCR, fluorescent droplets were read on the 
FACS-like Bio-Rad QX200 Automated Droplet Reader. After the droplets were read, the negative control 
reactions for each target were used to set the positive/negative threshold using the Quantasoft software 
(Bio-Rad). Once the thresholds were set, copies/µl could be determined for each sample well using the 
 14 
 
Quantasoft software. These copies/µl values were used to calculate HIV/µl in each original sample. This 
quantity of HIV-1 DNA was used to inform the dilution needed for end-point dilution of the DNA for the 
PCR to obtain single genome amplification of the HIV-1 DNA which was used to generate full-length env 
genes using the primers and materials described above. These env genes were bidirectionally sequenced 
with Sanger sequencing. Copies of HIV-1 DNA per 1 million cells were also calculated and these 
concentrations were compared between liver and lymph node samples using an unpaired t test with 
GraphPad Prism 9 software.  
Phylogenetic analyses: Full-length env genes were aligned using multiple sequence comparison 
by log-expectation (MUSCLE) [59] and neighbor-joining phylogenetic trees were constructed and 
visualized using FigTree v1.4.4 software (http://tree.bio.ed.ac.uk/software/figtree/). Bootstrap values were 
calculated with 500 replicates using MEGAX software [60]. Slatkin-Maddison p values were calculated 
with 10,000 permutations using HyPhy v2.2.4 software to identify compartmentalized CSF populations 
[61].  
Construction of HIV-1 env clones: SGA amplicons to be cloned were selected based on each 
participant’s phylogenetic tree structure. Each full length env gene was re-amplified from first round SGA 
products using Phusion High Fidelity polymerase (New England Biolabs) and the primers B5957F-TOPO 
(5’- CACCTTAGGCATCTCCTATGGCAGGAAGAAG-3’) and B8904R-TOPO (5’-
GTCTCGAGATACTGCTCCCACCC-3’) following the manufacturer’s instructions. These re-amplified 
amplicons were then gel purified using QIAquick Gel Extraction kit (Qiagen) and the purified env genes 
were cloned into pcDNA3.1D/V5-His-TOPO expression vector (Invitrogen) using the pcDNA 3.1 TOPO 
expression kit (Invitrogen) and the entire cloning reaction was transformed into MAX Efficiency Stbl2 
competent cells (Invitrogen) as per the manufacturer’s instructions. Bacterial colonies were screened for 
the insertion of the env gene using colony PCR where individual colonies were picked and added directly 
to a PCR master mix (primers B5957F-TOPO and B8904R-TOPO). 3 mL overnight cultures were made 
for 3-6 positive colonies for each env gene and DNA was extracted using the QIAprep Spin Miniprep Kit 
(Qiagen). 
 Cells: 293T cells were cultured using Dulbecco’s modified Eagle medium (DMEM) with 10% fetal 
bovine serum (FBS) and 100 mg/ml of penicillin and streptomycin. 293-Affinofile cells [62], which were 
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generously provided by Dr Ben-Hur Lee, were maintained in DMEM supplemented with 10% dialyzed 
FBS (12-14 kD dialyzed, Atlanta Biologicals) and 50 mg/ml blasticidin (D10F/B).  
Env-pseudotyped viruses: Env-pseudotyped luciferase reporter viruses were generated as 
previously described [40]. Briefly, 293T cells were co-transfected with an env expression vector and the 
pNL4-3.LucR-E-HIV-1 backbone (obtained from the NIH HIV Reagent Program) using the Fugene HD 
transfection reagent protocol (Promega). Transfection medium was replaced with fresh culture medium 
~18 hours post-transfection and the cells were incubated at 37oC for an additional 24-36 hours. Viral 
supernatants were then filtered with 0.45 µM filters (Millipore) and stored in aliquots at -80oC.  
Affinofile surface expression of CD4 and CCR5: Affinofile cell CD4 and CCR5 receptor 
expression was induced with doxycycline (doxy; Invitrogen) and ponasterone A (ponA; Invitrogen), 
respectively as previously described [40]. Briefly, cells were induced at two conditions: CD4high/CCR5high 
(6 ng/ml doxy and 5 µM ponA, respectively) and CD4low/CCR5high (0 ng/ml doxy and 5 µM ponA). CD4 
and CCR5 receptor expression was measured using quantitative fluorescence-activated cytometry 
(qFACS) following staining with either phycoerythin (PE)-conjugated anti-human CD4 antibody (clone 
Q4120, BD Biosciences) or PE-conjugated mouse anti-human CCR5 antibody (clone 2D7, BD 
Biosciences), and surface levels were calculated using QuantiBRITE beads (BD Biosciences). 
Single cycle infection of Affinofile cells: The ability of expressed Env proteins to mediate entry into 
cells expressing a low surface density of CD4 was assessed using our established protocol [63]. Briefly, 
pseudoviruses containing the Env protein of interest with a luciferase reporter gene were first titered on 
Affinofile cells expressing CD4high/CCR5high. In order to ensure that each infection assay was performed 
within the linear range, I used a volume of virus needed to produce 800,000 relative light units (RLU) as 
calculated from the titering experiment. For infections, black 96-well tissue culture plates were coated with 
10% poly-L-lysine and incubated at 37oC for 20 minutes. The poly-L-lysine was removed and the inner 60 
wells were seeded with 100 µl of Affinofile cells at 1.8 x 105 cells/ml (100 µl of phosphate-buffered saline 
(PBS) was added to the outer wells).  Expression of CD4 and CCR5 was induced at CD4high/CCR5high and 
CD4low/CCR5high 18 to 24 hours later. Eighteen to 24 hours after induction, the infection medium was 
removed and replaced with 50 µl of fresh, warmed medium. Pseudovirus was diluted to a volume 
appropriate for inducing 800,000 RLU into 50 µl of medium and the 50 µl of medium mixed with 
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pseudovirus was added to the cells. The infection plates were then spinoculated at 2,000 rpm for 2 hours 
at 37oC. The plates were removed from the centrifuge and incubated for an additional 48 hours at 37oC. 
Infection medium was then removed, the cells were gently washed twice with PBS, lysed, covered, and 
frozen at -80oC. After a minimum of 2 hours of being frozen, the plates were warmed to thaw the cell 
lysates and luciferase activity was assayed using the luciferase assay system (Promega).  
 
Results 
Study population and characterizing blood and CSF virus 
 In this study, I identified four participants from the National NeuroAIDS Tissue Consortium 
(NNTC) each of which had a HAD diagnosis, a plasma HIV-1 RNA viral load of at least 5,000 copies/ml to 
increase the likelihood of adequate viral load in the CSF for sequence analysis, and who also had 
available blood plasma, CSF, liver tissue, and lymphoid tissue samples. All participants were not on cART 
at the time of death and sample collection, and all had a plasma CD4+ T cell count less than 300 cells/µl 
(Table 1) with a median value of 84 cells/µl. The median plasma HIV-1 RNA viral load was 518,655 
copies/ml and the median CSF HIV-1 RNA viral load was 16,999 copies/ml.  
 Viral RNA was extracted from the plasma and CSF samples and used to amplify full length env 
genes using an SGA protocol. The env genes were then sequenced. Neighbor-joining phylogenetic trees 
were built with the full-length env gene sequences to identify participants with CSF compartmentalized 
virus. Compartmentalized lineages were identified by i) visual inspection for a heterogenous CSF-specific 
lineage, ii) bootstrap support for the lineage, and iii) the Slatkin-Maddison tree-based statistical test for 
compartmentalization (p values in Table 1). Two of the four participants analyzed (6800127569 and 
30005) had compartmentalized CSF virus and two participants (7200537480 and 10129) had equilibrated 
plasma and CSF virus with no evidence of compartmentalization (Table 1 and Figure 2.1A). To assess 
the ability of these viruses to enter cells with low surface levels of CD4 (i.e., macrophage-tropic entry 
phenotype), I used our established Affinofile virus entry assay. Both of the participants with 
compartmentalized CSF virus, 6800127569 and 30005, had macrophage-tropic virus in the CSF while the 
two participants with equilibrated blood and CSF virus, 7200537480 and 10129, had no evidence of 




Table 1: Participant demographics.  
Data was not measured or not available for fields marked with ‘-.’  
P values generated by Slatkin-Maddison tree-based test for compartmentalization. Trees with p < 0.05 


































UT Galveston 7200537480 M Asian 40,133 2,747 299 - Yes Positive 0.2495
UT Galveston 6800127569 M White >750,000 >750,000 49 - Yes - <0.0007
Mt Sinai 10129 M Black or African American >750,000 328 52 1 Yes Negative 0.4637




Figure 2.1: Compartmentalization and phenotype in the blood and CSF.  
A. Neighbor-joining phylogenetic trees of full-length env genes amplified by SGA from HIV-1 RNA in the 
blood plasma (red triangles) and CSF (blue circles) for each participant. Bootstrap values are included at 
nodes in the tree where the value was >70. Compartmentalized CSF lineages in participants 6800127569 
and 30005 are marked with a blue circle at the node. env genes that were cloned and phenotyped are 
marked with a black star. B. Results from Affinofile virus entry assay. The percent infectivity at low CD4 
surface density relative to the infectivity at high CD4 surface density is plotted for a macrophage-tropic 
virus control (BaL gray), a T cell-tropic virus control (JRCSF, gray), as well as representative env genes 
isolated from the blood plasma (red) and the CSF (blue) for each participant. Compartmentalized CSF 





















































































































































































































I hypothesized that in participants where macrophage-tropic virus evolves in the CNS, that virus 
may be able to travel to the macrophage-rich liver and maintain the macrophage-tropic phenotype there. 
To assess virus in tissue I switched to amplifying viral DNA, again focusing on full length env genes and 
an SGA protocol. After having identified representative participants with and without compartmentalized 
macrophage-tropic virus in the CNS, I examined virus in the liver tissue and lymphoid tissue (a 
presumably T cell-tropic proviral population for comparison) to look for macrophage-tropic HIV variants 
from the CSF lineage in the liver.  Droplet digital PCR (ddPCR) allowed me to quantify the HIV proviral 
genomes in the total DNA extracted from the tissue samples. These quantifications were subsequently 
used to inform dilutions for amplification of env genes via SGA.  
Evidence of local HIV-1 replication in the liver and lymph node 
 Participants 7200537480 and 10129 had no compartmentalized or macrophage-tropic virus in the 
CSF and therefore I did not expect to see macrophage-tropic virus in the liver of these participants. 
However, phylogenetic analysis did show evidence of local viral replication (compartmentalization) in the 
liver as well as in the lymphoid tissue. This pattern was most striking in participant 10129 where distinct 
compartmentalized viral lineages supported by high bootstrap values were identified in both the liver and 
lymph node tissue (Figure 2.2A). env gene sequences from the liver and spleen in participant 
7200537480 also clustered together in parts of the phylogenetic tree though the bootstrap support was 
not as strong (Figure 2.2A).  
 I then used our Affinofile virus entry assay to determine the cellular tropism of the encoded Env 
proteins isolated from the tissue samples. All Env proteins tested from all tissues were T cell-tropic, that is 
they were unable to infect cells with low levels of CD4 on the surface (Figure 2.2B). The 
compartmentalized viral lineages in the liver and lymph node suggests local replication occurs within each 
tissue, and the phenotype assay confirms this replication was happening in T cells in both compartments. 
In this limited sampling, I saw no evidence of macrophage-tropic virus in the liver of participants who had 





Figure 2.2: HIV-1 DNA in the liver and lymphoid tissue of two equilibrated participants.  
A. Neighbor-joining phylogenetic trees of full-length env genes amplified by SGA from HIV-1 RNA in the 
blood plasma (red triangles), CSF (blue circle), and HIV-1 DNA in the liver (black squares), spleen (gold 










































































































































the tree where the value was >70. Compartmentalized lineages are noted with a circle. env genes that 
were cloned and phenotyped are marked with a black star. B. Results from Affinofile virus entry assay. 
The percent infectivity at low CD4 density relative to the infectivity at high CD4 density is plotted for a 
macrophage-tropic control virus (Bal, gray), a T cell tropic control virus (JRCSF, gray), as well as 
representative env genes isolated from the blood plasma (red), CSF (blue), liver (black), spleen (gold), 

























Little evidence of macrophage-tropic virus from the CNS establishing or maintaining macrophage-
tropic lineages in the liver 
 Participants 6800127569 and 30005 both had macrophage-tropic virus in the CSF, a scenario I 
hypothesized could lead to the detection of macrophage-tropic virus in the liver, an organ with a relatively 
high number of potential low CD4 target cells where this phenotype might be maintained. Between these 
two participants with macrophage-tropic virus in the CSF, our phylogenetic analyses of viral sequences in 
the liver indicated one possible liver virus that migrated from the CSF/CNS (participant 6800127569, 
Figure 2.3A). This one sequence was a full-length, intact env gene but it did have some unique 
differences in the nucleotide sequence and in sequence length in the V1V2, V4, and V5 regions of env 
compared to the rest of the CSF lineage, hence the longer branch length. I was unfortunately unable to 
test the entry phenotype of the Env protein encoded in this gene.  
 The majority of liver and lymph node sequences from participants 6800127569 and 30005 were 
equilibrated with the viral sequences isolated from the blood plasma (Figure 2.3A). These envelopes were 
all T cell-tropic when tested for cell tropism with the Affinofile assay (Figure 2.3B). Unlike participants 
7200537480 and 10129, there was not evidence of compartmentalization or local replication within the 















































































































































Figure 2.3: HIV-1 DNA in the liver and lymphoid tissue of two compartmentalized participants. 
A. Neighbor-joining phylogenetic trees of full-length env genes amplified by SGA from HIV-1 RNA in the 
blood plasma (red triangles), CSF (blue circle), and HIV-1 DNA in the liver (black squares), and lymph 
node (green squares). Bootstrap values are included at nodes in the tree where the value was >70. 
Compartmentalized CSF viral lineages are marked with a blue circle. Recombinant env genes are marked 
with a purple bar. env genes that were cloned and phenotyped are marked with a black star. B. Results 
from Affinofile virus entry assay. The percent infectivity at low CD4 cell surface density relative to the 
infectivity at high CD4 cell surface density is plotted for a macrophage-tropic virus control (Bal, gray), a T 
cell-tropic virus control (JRCSF, gray), as well as representative env genes isolated from the blood 
plasma (red), CSF (blue), liver (black), and lymph node (green). As seen in Figure 1B, the 
compartmentalized CSF virus from both participants was macrophage-tropic, all env genes from the 
tissue encoded Env proteins that were T cell-tropic. C. Highlighter plots comparing the nucleotide 
sequence of all env genes isolated from participants 6800127569 and 30005. All sequences are 
compared to a chosen master sequence at the top of the plot. Each nucleotide change from the master 
sequence is marked with a colored tick mark in subsequent sequences. Recombinant env genes are 
marked with a purple bar, the main blood lineage of virus is marked with a red bar, and the main CSF 
lineage of virus is marked with a blue bar. env genes that were tested for entry phenotype are marked 
with a red star (T cell-tropic) or blue star (macrophage-tropic). Recombinant env genes have sequence 












Recombinant viral variants are detected in the liver 
 While I did not find convincing evidence of macrophage-tropic viruses in the liver, I did see 
recombinant viral variants in the tissue of both participants with macrophage-tropic virus in the CSF 
(Figure 2.3A and 2.3C). These recombinant env genes have nucleotide sequence patterns that are 
specific to the macrophage-tropic virus in the CSF compartment mixed with patterns that are specific to 
the T cell-tropic virus in the blood compartment. This is evident on the highlighter plots (Figure 2.3C) 
where sequence signatures from both the CSF and plasma lineages, marked with blue and red bars 
respectively, are present in the recombinant env genes (purple bar). In the phylogenetic trees, the 
recombinants branch between the CSF and blood lineages. These recombinant variants were seen in the 
liver of both participants. Salazar-Gonzalez et al. demonstrated that recombinant artifacts that are 
generated in vitro by bulk PCR are not seen when end-point dilution is done as part of an SGA protocol 
[64]. Therefore, I assume the recombinants observed here were produced in vivo.  Recombinant env 
genes were also seen in the lymph node, plasma, and CSF of participant 30005. A subset of these 
recombinant env genes were tested for cell tropism and all required a high surface density of CD4 for 















Figure 2.4. Quantification of HIV-1 DNA in liver and lymph nodes.  
HIV-1 DNA copies (as measured by gag positive droplets in the ddPCR assay) per 1 million cells (as 
measured by RPP30 positive droplets) are plotted for the liver (black squares) and the lymph nodes 
(green squares) of all participants where the samples were available (liver n = 4, lymph node n = 3). The 
mean value for each tissue is marked with a black bar. An unpaired t test of these values gave a 


































There is significantly more HIV-1 proviral DNA in lymph nodes compared to the liver 
 I was able to quantify the copies of HIV-1 DNA per million cells in the tissues using ddPCR for 
both HIV-1 DNA (probing for gag gene sequences) and a cellular gene, RPP30, in order to calculate the 
number of cells represented. Though I analyzed liver from only 4 participants and lymph nodes from only 
3 participants, the amount of HIV-1 DNA in these tissues was significantly different. In the liver, there was 
an average of 0.23 copies of HIV-1 DNA per 1 million cells (range of 0.09 – 0.35 HIV-1 DNA copies per 
million cells) but in the lymph nodes there was an average of 7.5 HIV-1 DNA copies per 1 million cells 
(range of 2.9 – 11.7 HIV-1 DNA copies per million cells). An unpaired t test on these values yielded a p 
value of 0.02 indicating a significantly higher frequency of HIV-1 DNA in lymph nodes compared to liver 
(Figure 2.4). This is consistent with the high number of high CD4 density target cells (i.e., T cells) in the 
lymph nodes and the lack of detection of macrophage-tropic virus outside of the CNS.  
 
Discussion 
It has been previously reported that there is a high frequency of compartmentalization of HIV-1 
within the CNS with a macrophage-tropic phenotype in PLWH who are untreated, are late in disease, and 
who have been diagnosed with severe neurological disease [29, 31]. My initial study, described here, was 
limited to four such participants where two of the four had CSF compartmentalized virus and both of the 
participants with compartmentalized virus had macrophage-tropic virus in the CSF/CNS. These 
characteristics theoretically create favorable conditions for observing macrophage-tropic virus from the 
CNS traveling to other macrophage-rich tissues in the body if such a pattern were possible. I examined 
this possibility by looking for macrophage-tropic virus in the liver that was related to virus in the CNS. 
While I did not find macrophage-tropic virus in the liver I did identify recombinants of virus in the CNS and 
the blood suggesting virus from the CNS had migrated to the liver but then lost its macrophage-tropic 
phenotype due to recombination with T cell-tropic virus. 
 In both participants with compartmentalized macrophage-tropic virus in the CSF, I found env 
gene variants in the tissue samples that were recombinants between the T cell-tropic virus in the blood 
compartment and the macrophage-tropic virus in the CSF/CNS compartment. In order for two variants to 
recombine, they must infect the same cell where for the different viral genomes to be packaged into a 
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new virion and for recombination to occur during the next round of infection. Previous studies have 
suggested that multiply infected naïve and memory CD4+ T cells in the peripheral blood and the lymph 
node are rare, ~7-25% [65] but also that the frequency of T cells infected is higher in the lymph node 
(0.4% of memory cells) compared to the frequency of infected T cells in the peripheral blood (0.14% of 
memory cells). So, while multiply infected cells are rare, they may be more easily detected in the lymph 
node given the higher percentage of infected cells. Additionally, it is unknown if these infection patterns 
hold true in the liver or if other CD4+ permissive cells (macrophages, Kupffer cells) are multiply infected at 
the same rate, although the level of infection of macrophages in the liver by T-tropic virus would be 
especially low. I did not find direct evidence of macrophage-tropic virus in the liver but the data in this 
limited sampling fit a model where macrophage-tropic virus in the CNS traveled to the liver where it was 
able to replicate, potentially initially in macrophages, and then recombine with the virus in the blood 
compartment as viral replication moved into the more abundant CD4+ T cells. As there is no need for the 
virus to maintain the macrophage-tropic phenotype in the liver where there are plenty of T cells with a 
high density of surface CD4 in the surrounding tissue and blood, it is plausible that phenotype is quickly 
lost as the virus recombines. The recombinants tested for entry phenotype were all T cell-tropic and 
unable to enter cells with a low surface density of CD4.  
In these two participants with compartmentalized macrophage-tropic virus in the CSF, I saw one 
single example of a viral env gene in the liver that branched within one of these CNS viral lineages 
(participant 68001277569). This env gene was full-length and intact but did have some unique nucleotide 
changes and length variabilities in the V1V2, V4, and V5 variable regions giving it a longer branch length 
than other sequences in the same lineage. I have been unsuccessful in cloning this sequence to test its 
entry phenotype as a pseudovirus. If this env gene does encode a functional protein, I would predict it 
would be macrophage-tropic like the other three CSF-derived env genes tested from the same lineage. 
Generating additional viral sequences from the liver of this participant may identify additional liver-derived 
sequences in this compartment that I am able to phenotype. Additionally, this participant was the only 
participant in our small cohort who was confirmed HCV positive (two equilibrated participants were HCV 
negative and the other compartmentalized participant had an unknown HCV status, Table 1). One study, 
Vail et al. [66], found that people with HIV/HCV coinfection had significantly lower numbers of CD4+ T 
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cells in the liver compared to people who were mono-infected with HIV-1. This may be one possible 
explanation for the one potential macrophage-tropic viral env gene being detected in the liver in this 
coinfected individual. Examining HIV-1 env populations in additional HIV-1 and HCV coinfected 
individuals would help determine 
  An unexpected finding in the two participants with equilibrated virus in the blood and CSF was 
evidence of compartmentalization and local replication in other tissue compartments. Proviral sequencing 
of HIV-1 in tissues of untreated PLWH has been largely unexplored. All envelopes from these tissue 
compartments that were tested for cell tropism were T cell-tropic indicating that HIV-1 is able to replicate 
locally in the liver, lymph node, and possibly the spleen in T cells. Joseffson et al. [65] reported genetic 
similarity between HIV-1 in the peripheral blood and HIV-1 in the lymph nodes of untreated people. The 
five participants in that study, however, were generally younger, infected for a relatively short time on 
average, and had higher CD4+ T cell counts compared to the four participants in our study who all died 
with late-stage disease. These differences may account for our different findings with regards to tissue 
compartmentalization. In terms of a cure to HIV-1, it is important to assess whether these T cell 
compartments in tissues respond the same way as provirus in the peripheral blood to any potential 
intervention. It would also be helpful to determine if similar patterns are seen in tissues of participants on 
suppressive cART. Characterizing the provirus in the tissues in these ways would help build a more 
comprehensive treatment and/or cure approach.  
the extent to which coinfection could affect the ability to detect macrophage-tropic virus in the liver. 
 ddPCR allowed for the quantification of HIV-1 DNA in each tissue sample and compare this 
concentration between tissues. Consistent with previous reports [67, 68], there was a high concentration 
of HIV-1 DNA in the lymph nodes of these participants. Specifically, the HIV-1 DNA concentration in the 
lymph node of our participants as measured by the detection of gag, was significantly higher than the 
HIV-1 DNA concentration in the liver. These results are consistent with the large pool of permissive cells 
in the lymph node compared to the liver, especially in the absence of the ability to infect cells with a low 
density of CD4.  
 The main limitation of this study is sample size (number of people) and sampling depth (number 
of sequences for each biological sample). I obtained sequences from only four individuals and the 
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sampling depth of viral sequences from each tissue compartment was limited. Additional sequences from 
each tissue as well as additional participants to examine would be helpful in determining the potential 
significance of these findings as the sensitivity of detection is directly related to the number of 
observations. Thus, additional participants (limited by the criteria for inclusion in the study) and additional 
sequences (limited by the labor-intensive nature of generating the sequences) would strengthen the 
conclusions. However, the patterns I did see were consistent enough to draw some general conclusions. 
First, macrophage-tropic viruses are not easily found in the liver, even in participants with macrophage-
tropic viruses in the body (CNS) late in disease. Second, in participants with macrophage-tropic virus in 
the CSF/CNS, proviral recombinant env genes between the blood compartment and CSF compartment 
can be detected in the liver suggesting macrophage-tropic variants do leave the CNS and recombine with 
the blood virus in the liver though they may quickly lose their macrophage-tropic entry phenotype. Third, 
compartmentalized viral replication can be detected in the liver, the lymph node, and possibly the spleen 
of participants with advanced disease. This replication happens in T cells and this pattern is more obvious 





















CHAPTER 3: SUMMARY AND FUTURE DIRECTIONS 
 
The frequency of CSF compartmentalization (50%) and macrophage-tropism in 
compartmentalized CSF populations (100%) in this small study were consistent with what has been 
reported in previous studies [29, 31]. These conditions created a potentially favorable environment for 
observing macrophage-tropic HIV-1 in other parts of the body. Macrophage-tropic virus has been 
reported in the male genital tract [41] and is rarely found in the blood [33, 54]. Virus in the blood likely 
comes from multiple sources (PBMCs, lymphatic tissues, mucosal tissues) and it is possible that the 
overwhelming number of T cell-tropic viruses from these sources make it difficult to detect a rare 
macrophage-tropic variant. Little is known about the potential for macrophage-tropic virus to exist in other 
anatomical compartments outside the CNS. As the organ with the highest concentration of tissue 
macrophages in the body, the liver is a tissue where macrophage-tropic virus could potentially travel from 
the CNS and continue to replicate. I examined proviral DNA from liver tissue taken at autopsy to look for 
this pattern. I found one potential example of a macrophage-tropic env gene in the liver. This env is a full-
length, intact gene that branches with the macrophage-tropic CSF lineage, but I have been unable to 
confirm the entry phenotype with our Affinofile assay. If we assume the encoded Env protein is low CD4 
using, as are all Env proteins we have tested previously that branch in a macrophage-tropic lineage, I 
would still conclude that observing macrophage-tropic virus in the liver is uncommon, even in people with 
end stage disease. Analyzing additional env genes from the liver of this particular participant 
(6800127569) might produce an additional example of a liver env branching with the macrophage-tropic 
CSF lineage for which the entry phenotype can be measured. However, there were examples of 
recombinant env genes in the liver of both compartmentalized participants. These env genes were 
comprised of genetic patterns present in the main CSF lineage but not the main blood lineage and vice 
versa. The existence of these recombinants does not prove the existence of macrophage-tropic virus in 
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the liver but it is consistent with a model where macrophage-tropic virus from the CSF/CNS travels to the 
liver where it can infect the same host cell as a virus from the blood lineage and recombine to create a 
new variant. The recombinants tested were T cell-tropic implying that the macrophage-tropic phenotype is 
quickly lost in an environment with plenty of high CD4 target cells. Additionally, our sequence analysis 
revealed examples of compartmentalized replication in both the liver and the lymph node and phenotype 
analysis confirmed this replication was happening in T cells. Taken together, our results support a model 
of advanced HIV-1 disease where virus can replicate in tissue compartments and in the CSF/CNS. 
Additionally, macrophage-tropic virus can travel out of the CNS and to the liver where it replicates, in T 
cells or macrophages, and quickly loses the ability to infect cells with low CD4, presumably due to a 
fitness cost as well as the abundance of high CD4 cells there. However, the fact that we see these 
recombinants in the liver but not the blood suggests that macrophage-tropic viruses exiting the CNS may 
initially replicate in macrophage-lineage cells in the liver. Animal model studies where serial sampling is 
possible may help elucidate the sequence of events. 
 Increasing the depth of sampling, ideally n = 20 for each tissue, for these participants and 
sampling additional participants would strengthen the conclusions and potentially allow for the formulation 
of a more specific model of viral dynamics in the liver of late stage HAD patients. In particular, additional 
sampling of viral sequences from the liver from participant 6800127569 may reveal additional env genes 
that are part of the macrophage-tropic CSF lineage which may allow us to measure the entry phenotype 
and more definitively conclude if it is possible for macrophage-tropic HIV-1 to exist in the liver. In 
participants 7200537480 and 30005, sequences from the liver (7200537480), spleen (7200537480), and 
lymph node (30005) clustered together on the phylogenetic tree but these compartments did not have the 
same bootstrap support as the liver and lymph node compartmentalized lineages in participant 10129. 
Additional sequences from these tissues for 7200537480 and 30005 may allow us to assess more 
accurately the frequency with which compartmentalized virus is seen in these tissues. We also have 
blood, CSF, and liver tissue from additional HAD participants to examine to determine if these patterns 
remain consistent.   
 The integration of HIV-1 proviral DNA into host cell genomes and the creation of a latent viral 
reservoir is the major barrier to a cure for HIV-1. The first studies proving the existence of an inducible, 
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replication-competent reservoir were done in CD4+ T cells lacking activation markers [9-11, 69] and the 
reservoir in this cell type remains the most well-characterized reservoir of latent HIV-1 to date. Moreover, 
most of what is known about cells that contribute to the HIV-1 reservoir has been determined using 
peripheral blood. In recent years, studies have been done to understand how different T cell subsets in 
the periphery might contribute to the reservoir [14, 70-73] and also to characterize potential reservoirs in 
tissues such as the gut [74, 75], and secondary lymphatic tissues [76, 77]. In addition to various T cell 
populations, it has been reported that macrophages are permissive to HIV-1 infection and thus assessing 
the potential of this cell type to contribute to the reservoir is important when considering cure strategies. 
In the CNS of untreated people, compartmentalized virus adapted to replicating in T cells and 
macrophages has been observed. Additionally, in a small percentage of people on cART and virologically 
suppressed in the peripheral blood, HIV-1 can continue to replicate in the CNS [34] though the 
mechanisms of this phenomenon are poorly understood. Future studies examining viral populations in 
other macrophage-rich tissues, such as the lung, as well as studies of proviral populations in tissues of 
ART-treated people would help determine what, if any, role macrophages play in the viral reservoir.  
 In summary, evaluating the potential of a myeloid HIV-1 reservoir is essential to developing an 
effective cure strategy. While multiple reports suggest myeloid cells are permissive to HIV-1 infection in 
vivo, it is unclear whether these cells harbor latent provirus and contribute to the rebound viral load upon 
cART discontinuation. If myeloid cells can be latently infected, any potential cure strategy would need to 
reach potential reservoir cells, that is be able to cross the BBB and reach therapeutic levels in the CNS. 
Additionally, latency reversing agents (LRAs) have been shown to be effective at inducing the latent 
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